Efficacy and Safety of Cyclophosphamide in Pediatric Patients With Steroid-Refractory Acute Disseminated Encephalomyelitis (ADEM) (CYC-ADEM-Peds)
A Randomized, Open-Label, Comparative Clinical Trial Evaluating the Efficacy and Safety of Cyclophosphamide Versus Intravenous Immunoglobulin (IVIG) in Pediatric Patients With Steroid-Refractory Acute Disseminated Encephalomyelitis
Acute Disseminated Encephalomyelitis (ADEM) is a severe, immune-mediated demyelinating disease of the central nervous system predominantly affecting the pediatric population. Although high-dose intravenous corticosteroids (such as methylprednisolone) represent standard first-line therapy, a subset of clinical cases fails to achieve adequate clinical response, carrying high risks of persistent neurological disability, neurodevelopmental sequelae, or fulminant deterioration.
This randomized, open-label trial evaluates the clinical efficacy, neuroimaging outcomes, and safety profile of intravenous cyclophosphamide pulse therapy compared with intravenous immunoglobulin (IVIG) as a rescue modality in pediatric patients under 14 years of age with steroid-refractory ADEM. Eligible participants are allocated using a computer-based random number generator. Enrolled patients are prospectively monitored for neurological recovery, functional disability using the pediatric Liverpool Outcome Score (LOS), radiological resolution on neuroimaging (MRI), overall survival, and treatment-emergent adverse events.
Descripción general del estudio
Estado
Estado
Condiciones
Condiciones
Intervención / Tratamiento
Intervención / Tratamiento
Descripción detallada
Acute Disseminated Encephalomyelitis (ADEM) is an immune-mediated demyelinating inflammatory disorder of the central nervous system predominantly affecting pediatric patients. While high-dose intravenous corticosteroids (such as methylprednisolone) serve as the standard first-line treatment, a clinical subset of patients fails to respond, presenting persistent neurological deficits, neurodevelopmental sequelae, or fulminant clinical deterioration.
This prospective, randomized, open-label comparative clinical trial is designed to evaluate the therapeutic efficacy, neuroimaging resolution, and safety profile of intravenous cyclophosphamide pulse therapy compared with intravenous immunoglobulin (IVIG) as a standard second-line immunomodulatory therapy in pediatric patients under 14 years of age with steroid-refractory ADEM.
Eligible participants (a total of 30 pediatric patients) are randomized in a 1:1 ratio using a computer-generated random number sequence into two equal treatment arms: 15 patients in the experimental arm receive intravenous cyclophosphamide pulse therapy (500 mg/m2) combined with intensive hydration and Mesna uroprotection to prevent hemorrhagic cystitis, while 15 patients in the active comparator arm receive standard intravenous immunoglobulin (IVIG) immunomodulatory therapy (2 g/kg).
Longitudinal monitoring is performed across both cohorts to assess neurological functional recovery and disability using the pediatric-validated Liverpool Outcome Score (LOS), radiological clearance on brain and spine MRI, overall survival up to 24 months, and the active surveillance of treatment-emergent adverse events.
Tipo de estudio
Tipo de estudio
Inscripción (Estimado)
Inscripción
Fase
Fase
- Fase 2
Contactos y Ubicaciones
Estudio Contacto
Estudio Contacto
- Nombre: Fatima Amer, MD
- Número de teléfono: +963 966494768
- Correo electrónico: Fatema.amer@damascusuniversity.edu.sy
Ubicaciones de estudio
-
-
-
Damascus, Siria
- Reclutamiento
- Children's University Hospital
-
Contacto:
- Fatima Amer, MD
- Número de teléfono: +963 966494768
- Correo electrónico: Fatema.amer@damascusuniversity.edu.sy
-
Investigador principal:
- Fatima Amer, MD
-
Investigador principal:
- Sameer Baqla, PhD
-
-
Criterios de participación
Criterio de elegibilidad
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria:
- Pediatric patients younger than 14 years of age (< 14 years) at clinical presentation.
- Confirmed diagnosis of Acute Disseminated Encephalomyelitis (ADEM) fulfilling the consensus criteria defined by the International Pediatric Multiple Sclerosis Study Group (IPMSSG).
- Steroid-refractory clinical status, defined as active disease persistence, neurological deterioration, or absence of significant functional improvement following a 3-5 day course of high-dose intravenous methylprednisolone pulse therapy (20-30 mg/kg/day).
- Intact baseline renal function (serum creatinine and BUN within age-adjusted normal physiological ranges).
- Intact baseline hepatic function (AST, ALT, and bilirubin within acceptable limits).
- Absence of active systemic sepsis, bacteremia, or acute uncontrolled systemic infection at baseline.
- Formal written informed consent obtained from parents or legal guardians.
Exclusion Criteria:
- Patients aged 14 years and older (≥ 14.0 years).
- Pre-existing significant renal insufficiency, acute kidney injury, or chronic renal disease.
- Pre-existing hepatic failure, cirrhosis, or acute severe hepatic injury.
- Active systemic sepsis or uncontrolled severe systemic infection.
- Pre-existing severe bone marrow suppression (baseline absolute neutrophil count ANC ≤ 1500/mm³ or platelet count < 50,000/mm³).
- History of known hypersensitivity to cyclophosphamide, Mesna, or immunoglobulin preparations.
- Alternative neuroinflammatory or metabolic diagnosis confirmed.
- Refusal of parents or legal guardians to grant written informed consent.
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
- Asignación: Aleatorizado
- Modelo Intervencionista: Asignación paralela
- Enmascaramiento: Ninguno (etiqueta abierta)
Número de brazos
Armas e Intervenciones
Grupo de participantes/brazoGrupo de participantes/brazo |
Intervención / TratamientoIntervención / Tratamiento |
|---|---|
|
Experimental: Cyclophosphamide IV
Fifteen pediatric patients (<14 years) with steroid-refractory ADEM randomized to this experimental group will receive intravenous cyclophosphamide pulse therapy as rescue treatment. |
Administered as intravenous pulse therapy at a dosage of 500 mg/m² body surface area. Delivered with intensive pre- and post-hydration protocols along with Mesna (2-mercaptoethane sulfonate sodium) uroprotection to mitigate acrolein-induced hemorrhagic cystitis. |
|
Comparador activo: Intravenous Immunoglobulin (IVIG)
Fifteen pediatric patients (<14 years) with steroid-refractory ADEM randomized to this active comparator group receive intravenous immunoglobulin (IVIG) as a standard second-line immunomodulatory therapy for ADEM. |
Administered at a total immunomodulatory dose of 2 g/kg body weight, infused according to standard pediatric institutional protocols (either 1 g/kg/day for 2 consecutive days or 400 mg/kg/day over 5 consecutive days), under continuous hemodynamic monitoring. |
¿Qué mide el estudio?
Medidas de resultado primarias
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Neurological Functional Outcome and Disability Assessment by Liverpool Outcome Score (LOS)
Periodo de tiempo: Assessed at hospital discharge, and longitudinally at 2, 4, and 12 weeks post-treatment initiation.
|
Evaluation of functional recovery and post-encephalitic neurological sequelae using the pediatric-validated Liverpool Outcome Score (LOS). The LOS stratifies pediatric neuro-outcomes into 5 distinct categories:
|
Assessed at hospital discharge, and longitudinally at 2, 4, and 12 weeks post-treatment initiation.
|
Medidas de resultado secundarias
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Radiological Resolution on Neuroimaging (Brain & Spine MRI)
Periodo de tiempo: Assessed at 2,4 and 12 weeks post-treatment initiation.
|
Quantitative and qualitative reduction or total resolution of hyperintense demyelinating lesions on T2/FLAIR sequences, resolution of contrast enhancement, and absence of new active or demyelinating lesions. |
Assessed at 2,4 and 12 weeks post-treatment initiation.
|
|
Overall Survival and All-Cause Mortality Rate
Periodo de tiempo: Up to 24 months
|
Proportion of pediatric patients surviving without fatal disease complications or fulminant progression throughout the study observation window. |
Up to 24 months
|
|
Treatment-Emergent Adverse Events & Tolerability
Periodo de tiempo: Inpatient stay and longitudinally at 1, 2, and 12 weeks post-treatment initiation.
|
Incidence and severity of adverse drug reactions including bone marrow suppression (CBC) and hemorrhagic cystitis (Urinalysis) |
Inpatient stay and longitudinally at 1, 2, and 12 weeks post-treatment initiation.
|
Colaboradores e Investigadores
Patrocinador
Patrocinador
Investigadores
Investigadores
- Investigador principal: Fatima Amer, MD, Department of Pediatric Neurology, Faculty of Medicine, Damascus University, Damascus, Syrian Arab Republic
- Director de estudio: Sameer Baqla, PhD, Department of Pediatric Neurology, Faculty of Medicine, Damascus University, Damascus, Syrian Arab Republic
- Director de estudio: Sally Kadoura, PhD, Department of Pharmaceutics and Pharmaceutical Technology, Faculty of Pharmacy, Damascus University, Damascus, Syrian Arab Republic
Publicaciones y enlaces útiles
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Inicio del estudio
Finalización primaria (Estimado)
Finalización primaria
Finalización del estudio (Estimado)
Finalización del estudio
Fechas de registro del estudio
Enviado por primera vez
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Publicado por primera vez
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización publicada
Última actualización enviada que cumplió con los criterios de control de calidad
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
- Trastornos posinfecciosos
- Enfermedades Cerebrales
- Enfermedades del Sistema Nervioso Central
- Enfermedades del Sistema Nervioso
- Procesos Patológicos
- Enfermedad crónica
- Atributos de la enfermedad
- Enfermedades autoinmunes
- Enfermedades del sistema inmunológico
- Enfermedades Autoinmunes del Sistema Nervioso
- Enfermedades desmielinizantes
- Leucoencefalopatías
- Condiciones Patológicas, Signos y Síntomas
- Enfermedades Autoinmunes Desmielinizantes, SNC
- Encefalomielitis Aguda Diseminada
- Aminoácidos, péptidos y proteínas
- Proteínas
- Químicos orgánicos
- Hidrocarburos
- Anticuerpos
- Inmunoglobulinas
- Inmunoproteínas
- Proteínas de la sangre
- Globulinas séricas
- Globulinas
- Mostaza de fosforamida
- Compuestos de mostaza de nitrógeno
- Compuestos de mostaza
- Hidrocarburos, halogenados
- Fosforamidas
- Compuestos organofosforados
- Isotipos de inmunoglobulina
- Inmunoglobulina G
- Ciclofosfamida
- Inmunoglobulinas Intravenosas
Otros números de identificación del estudio
Otros números de identificación del estudio
- MD-051124-349
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
producto fabricado y exportado desde los EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .